Tags

Type your tag names separated by a space and hit enter

Elevated endogenous cannabinoids in schizophrenia.

Abstract

Evidence suggests that cannabinoid receptors, the pharmacologcial target of cannabis-derived drugs, and their accompanying system of endogenous activators may be dysfunctional in schizophrenia. To test this hypothesis, we examined whether endogenous cannabinoid concentrations in cerebrospinal fluid of schizophrenic patients are altered compared to nonschizophrenic controls. Endogenous cannabinoids were purified from cerebrospinal fluid of 10 patients with schizophrenia and 11 non-schizophrenic controls by high-performance liquid chromatography, and quantified by isotope dilution gas-chromatography/mass-spectrometry. Cerebrospinal concentrations of two endogenous cannabinoids (anandamide and palmitylethanolamide) were significantly higher in schizophrenic patients than non-schizophrenic controls (p < 0.05). By contrast, levels of 2-arachidonylglycerol, another endogenous cannabinoid lipid, were below detection in both groups. The findings did not seem attributable to gender, age or medication. Elevated anandamide and palmitylethanolamide levels in cerebrospinal fluid of schizophrenic patients may reflect an imbalance in endogenous cannabinoid signaling, which may contribute to the pathogenesis of schizophrenia.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Clinical Psychiatry and Psychotherapy, Medizinische Hochschule Hannover, Germany.

    , , ,

    Source

    Neuroreport 10:8 1999 Jun 03 pg 1665-9

    MeSH

    Adult
    Arachidonic Acids
    Cannabinoids
    Chromatography, High Pressure Liquid
    Endocannabinoids
    Ethanolamines
    Female
    Gas Chromatography-Mass Spectrometry
    Humans
    Male
    Middle Aged
    Palmitic Acids
    Polyunsaturated Alkamides
    Schizophrenia

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't
    Research Support, U.S. Gov't, P.H.S.

    Language

    eng

    PubMed ID

    10501554

    Citation

    Leweke, F M., et al. "Elevated Endogenous Cannabinoids in Schizophrenia." Neuroreport, vol. 10, no. 8, 1999, pp. 1665-9.
    Leweke FM, Giuffrida A, Wurster U, et al. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10(8):1665-9.
    Leweke, F. M., Giuffrida, A., Wurster, U., Emrich, H. M., & Piomelli, D. (1999). Elevated endogenous cannabinoids in schizophrenia. Neuroreport, 10(8), pp. 1665-9.
    Leweke FM, et al. Elevated Endogenous Cannabinoids in Schizophrenia. Neuroreport. 1999 Jun 3;10(8):1665-9. PubMed PMID: 10501554.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Elevated endogenous cannabinoids in schizophrenia. AU - Leweke,F M, AU - Giuffrida,A, AU - Wurster,U, AU - Emrich,H M, AU - Piomelli,D, PY - 1999/9/29/pubmed PY - 1999/9/29/medline PY - 1999/9/29/entrez SP - 1665 EP - 9 JF - Neuroreport JO - Neuroreport VL - 10 IS - 8 N2 - Evidence suggests that cannabinoid receptors, the pharmacologcial target of cannabis-derived drugs, and their accompanying system of endogenous activators may be dysfunctional in schizophrenia. To test this hypothesis, we examined whether endogenous cannabinoid concentrations in cerebrospinal fluid of schizophrenic patients are altered compared to nonschizophrenic controls. Endogenous cannabinoids were purified from cerebrospinal fluid of 10 patients with schizophrenia and 11 non-schizophrenic controls by high-performance liquid chromatography, and quantified by isotope dilution gas-chromatography/mass-spectrometry. Cerebrospinal concentrations of two endogenous cannabinoids (anandamide and palmitylethanolamide) were significantly higher in schizophrenic patients than non-schizophrenic controls (p < 0.05). By contrast, levels of 2-arachidonylglycerol, another endogenous cannabinoid lipid, were below detection in both groups. The findings did not seem attributable to gender, age or medication. Elevated anandamide and palmitylethanolamide levels in cerebrospinal fluid of schizophrenic patients may reflect an imbalance in endogenous cannabinoid signaling, which may contribute to the pathogenesis of schizophrenia. SN - 0959-4965 UR - https://www.unboundmedicine.com/medline/citation/10501554/Elevated_endogenous_cannabinoids_in_schizophrenia_ L2 - http://Insights.ovid.com/pubmed?pmid=10501554 DB - PRIME DP - Unbound Medicine ER -